Monocyte chemoattractant protein-1 and CC-chemokine receptor-2 in severe hypercholesterolaemia

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 63, Issue 7-8, 2003, Pages 513-520

  Blomqvist, H M ^a,b   Olsson, A G ^a  

^a Clinical Research Center   (Sweden)

^b Clinical Research Centre   (Sweden)

Author keywords

C reactive protein; CC chemokine receptor 2; Hypercholesterolaemia; Inflammation; Monocyte chemoattractant protein 1; Pravastatin

Indexed keywords

C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CCR2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PRAVASTATIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEPTOR GENE; SINGLE BLIND PROCEDURE;

EID: 1642512388     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510310003274     Document Type: Article

References (26)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
2. Libby P. Atherosclerosis: the new view. Sci Am 2002; 286: 46-55.
3. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
4. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987; 84: 2995-8.
5. Illingworth D. 3-hydroxy-3-methylglutaryl-coenzyme. A reductase inhibitor. In: Betteridge DJ, Illingworth DR, Shepherd J, editors. Lipoproteins in health and disease: Arnold; London 1999. p. 1161-79.
6. Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 1999; 10: 543-59.
7. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839-44.
8. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230-5.
9. Strandberg TE, Vanhanen H, Tikkanen MJ. Associations between change in C-reactive protein and serum lipids during statin treatment. Ann Med 2000; 32: 579-83.
10. van Wissen S, Trip MD, Smilde TJ, de Graaf J, Stalenhoef AFH, Kastelein JJP. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 2002; 165: 361-6.
11. Rollins BJ, Yoshimura T, Leonard EJ, Pober JS. Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am J Pathol 1990; 136: 1229-33.
12. Ikeda U, Matsui K, Murakami Y, Shimada K. Monocyte Chemoattractant protein-1 and coronary artery disease. Clin Cardiol 2002; 25: 143-7.
13. Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, Coughlin SR. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptor reveals alternative splicing of the carboxy-terminal tails. Proc Natl Acad Sci USA 1994; 91: 2752-6.
14. Han KH, Tangirala RK, Green SR, Quehenberger O. Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1-mediated chemotaxis in human monocytes. A regulatory role for plasma LDL. Arterioscler Thromb Vasc Biol 1998; 18: 1983-91.
15. Han KH, Han KO, Green SR, Quechenberger O. Expression of the monocyte chemoattactant protein-1 receptor CCR2 is increased in hypercholesterolemia: differential effects of plasma lipoproteins on monocyte function. J Lipid Res 1999; 40: 1053-63.
16. Boring L, Gosling J, Chensue SW, Kunkel SL, Jr RVF, Broxmeyer HE, Charo IF. Impared moncyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 1997; 100: 2552-61.
17. Gossling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Inv 1999; 103: 773-8.
18. Goldstein J, Hobbs H, Brown M. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic & molecular bases of inherited disease. 8th ed. New York: McGraw-Hill Medical Publishing Division; 2001. p. 2863-913
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
20. Ylä-Herttuala S, Lipton BA, Rosenfeld ME, Särkioja T, Yoshimura T, Leonard EJ, Witztum JL, Steinberg D. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991; 88: 5252-6.
21. Martinez-Gonzalez J, Alfon J, Berrozpe M, Badimon L. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 2001; 159: 27-33.
22. Rezaie-Majd A, Maca T, Bucek RA, Valent P, Muller MR, Husslein P, Kashanipour A, Minar E, Baghestanian M. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002; 22: 1194-9.
23. Wiklund O, Mattsson-Hultén L, Hurt-Camejo E, Oscarsson J. Effects of simvastatin and atornastatin on inflammatory markers in plasma. J Intern Med 2002; 251: 338-47.
24. Böttiger LE, Carlson LA, Ekelund LG, Olsson AG. Raised erythrocyte sedimentation rate in asymptomatic hyperlipidaemia. Br Med J 1973; 23: 681-4.
25. Pasceri V, Willerson JT, Yeh ETH. Direct Proinflammatory Effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-8.
26. Pasceri V, Chang J, Willerson JT, Yeh ETH. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531-4.